Navigation Links
Barr Confirms Patent Challenge of Eloxatin(R) Injectable, 5mg/mL
Date:1/9/2008

itive products and pricing on products, including the launch of authorized generics; the ability to launch new products in the timeframes we expect; the availability of raw materials; the availability of any product we purchase and sell as a distributor; the regulatory environment in the markets where we operate; our exposure to product liability and other lawsuits and contingencies; the increasing cost of insurance and the availability of product liability insurance coverage; our timely and successful completion of strategic initiatives, including integrating companies (such as PLIVA d.d.) and products we acquire and implementing our new SAP enterprise resource planning system; fluctuations in operating results, including the effects on such results from spending for research and development, sales and marketing activities and patent challenge activities; the inherent uncertainty associated with financial projections; our expansion into international markets through our PLIVA acquisition, and the resulting currency, governmental, regulatory and other risks involved with international operations; our ability to service our significantly increased debt obligations as a result of the PLIVA acquisition; changes in generally accepted accounting principles; and other risks detailed in our SEC filings, including in our Transition Report on Form 10-K/T for the six months ended December 31, 2006.

The forward-looking statements contained in this press release speak only as of the date the statement was made. The Company undertakes no obligation (nor does it intend) to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required under applicable law.


'/>"/>
SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Barr Confirms Patent Challenge of Focalin(R) XR
2. Recent Study Confirms Alimentary Healths Bifantis(R) Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome
3. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
4. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
5. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
6. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
7. Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics
8. DermTech Is Issued U.S. Patent for the Early Detection, Staging and Monitoring of Melanoma
9. Odyssey Thera Granted U.S. Patent for Animal Imaging
10. Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry
11. iCAD, Inc. Awarded Two Additional Patents for Its Computer-Aided Detection Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014 Research and Markets ... Isotope Ratio Mass Spectrometer Industry Report 2014" report ... Isotope Ratio Mass Spectrometer Industry Report 2014 is a ... the global isotope ratio mass spectrometer industry. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:8/27/2014)... 2014 Riviera Beach, Florida based ... creation of the Sancilio Scientific Advisory Board (SSAB). ... philosophy of looking to nature for pharmaceutical advancements, ... are based on sound scientific data, analyses, expertise ... provides a vehicle for SCI to receive peer ...
(Date:8/27/2014)... City, OR (PRWEB) August 27, 2014 ... Report, “Consolidation continues to reshape the look and feel ... nutrition. Consumer demand for higher-quality ingredients will push for ... North American market have experienced strong market growth in ... ethical attributes in their food and cosmetics to fit ...
(Date:8/27/2014)... Hunting Valley, Ohio (PRWEB) August 27, 2014 ... five students from Cleveland's University School ... at Case Western Reserve University’s School of ... program provides students with an unparalleled professional experience ... with the School of Medicine faculty and students ...
Breaking Biology Technology:Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3Students at Cleveland's University School Conduct Biomedical Research at Case Western Reserve University’s School of Medicine 2
... Monitorforhire.com, the,fastest source for hiring independent ... The company has added a mobile portal, ... to work requests via,PDA or cell phone ... president of monitorforhire.com says that adding the,capability ...
... in San Francisco on Wednesday, October ... ... 2 Favrille, Inc. (Nasdaq:,FVRL), a biopharmaceutical company developing patient-specific, active,immunotherapies ... Officer, will present at the Biotechnology,Industry Organization (BIO) InvestorForum at 10:15 ...
... Sciences, a Roche,company, and Perlegen Sciences, Inc., today ... in hundreds of DNA samples,collected by Perlegen from ... of drug. The goal of the collaboration will ... identified and,validated to create a clinical test that ...
Cached Biology Technology:New Pharmacogenomic Approach: 454 Life Sciences and Perlegen to Collaborate in Drug Response Sequencing Study 2New Pharmacogenomic Approach: 454 Life Sciences and Perlegen to Collaborate in Drug Response Sequencing Study 3
(Date:8/27/2014)... Outstanding basic research, a growing focus on translating ... care have earned the Herbert Irving Comprehensive Cancer ... and NewYork-Presbyterian Hospital an $18 million, five-year Cancer ... (NCI). The grant renews the center,s status as ... in New York City and one of only ...
(Date:8/27/2014)... studies have shown that excessive iron is ... disease. Previous studies from Chunyan Guo and ... have shown that baicalin prevented iron accumulation ... transporter 1 expression, and increased ferroportin 1 ... Parkinson,s disease rats. However, the relationship between ...
(Date:8/27/2014)... ago the Happy Camp Complex of fires had consumed ... complex had consumed 35,530 as of eight hours ago. ... Happy Camp Ranger District of the Klamath National Forest ... 11, 2014. All but three of those fires are ... of contained fires and their size at containment: Delta, ...
Breaking Biology News(10 mins):Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4Happy Camp and July Fire Complexes in California 2
... being able to predict the risk of disease or response ... a study by scientists at Washington University School of Medicine ... alone only tell part of the story. That,s because ... to predict, even in simple organisms like single-celled yeast, their ...
... Virginia Commonwealth University Massey Cancer Center led by Charles ... Biology, discovered a previously unknown mechanism in non-small cell ... to maintain and grow tumors. Narrowing in on this ... effective therapies for NSCLC and other cancers. ...
... 2010, Seoul, S. Korea Institut Pasteur Korea (IP-K) ... of Toulouse, France to continue research on the identification ... up in the fall of 2009, illustrates the value ... platform will be used to pinpoint active, non-toxic agents ...
Cached Biology News:The gene-environment enigma 2The gene-environment enigma 3VCU Massey discovery could lead to breakthrough for non-small cell lung cancer 2
... from Paraffin embedded tissue blocks, which are ... ensure the highest quality. Tissues of each ... sectioned at a thickness of 5 microns ... large (3-5 mm in diameter) in comparison ...
... tissue microarrays are derived from Paraffin embedded ... quality control procedures to ensure the highest ... assembled in one block, sectioned at a ... coated slides. Sections are large (3-5 mm ...
... Zyagen tissue microarrays are derived from ... to rigorous quality control procedures to ensure ... are manually assembled in one block, sectioned ... on coated slides. Sections are large (3-5mm ...
... are derived from Paraffin embedded tissue blocks, ... procedures to ensure the highest quality. Tissues ... one block, sectioned at a thickness of ... Sections are large (3-5mm in diameter) in ...
Biology Products: